Role of retroperitoneal lymph node dissection in clinical stage I Leydig cell tumours

Autor:	Fabio Vianello, R. Di Pietro, R. Bertoldin, S. Guazzieri, G. D'Incà, F. Di Tonno, D. Lavelli
Rok vydání:	1996
Předmět:	Chemotherapy Pathology medicine.medical_specialty Leydig cell business.industry medicine.medical_treatment General Medicine Leydig cell tumour medicine.disease Retroperitoneal lymph node dissection medicine.anatomical_structure Refractory Medicine Testicular tumours business
Zdroj:	Urologia Journal. 63:84-87
ISSN:	1724-6075 0391-5603
DOI:	10.1177/039156039606301s20
Popis:	Leydig Cell Tumours (LCT) account for 3% of all testicular tumours; 10% are malignant and are refractory to radio- and chemotherapy. The role of Retroperitoneal Lymph Node Dissection in clinical stage I LCT is therefore a particularly debated one. From March ‘83 to December ‘95, 10 patients with LCT were subjected to orchiectomy (1 of them bilaterally because of a metachronous tumour). In 10 out of 11 specimens the following pathological features – a) size larger than 50 mm, b) infiltration of spermatic cord, c) lymphatics and veins, d) capsule, e) necrosis, f) cellular pleomorphism, g) numerous mitoses, h) nuclear atypia – were absent. The only patient in which b) and d) were present was subjected to RPLND. After a follow-up ranging from 17 to 157 months all patients are disease-free. Abstention from RPLND in clinical stage I LCT therefore seems the more rational choice when the above- listed pathologic features are absent.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c0f1e5ecd7f12466da6a7e210d9bef3c https://doi.org/10.1177/039156039606301s20 Zobrazit plný text záznamu